Skip to main content

Day: June 29, 2021

Vision Marine Technologies Fast Tracks Commercialization of our E-Motion™ Electric Powertrain with Up to $1.72 Million (CAD) in Grants Secured from the Government of Quebec

Grants pave the way for Vision Marine to showcase its E-Motion™180 proprietary powertrain technology MONTREAL, June 29, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASAQ: VMAR) (“Vision Marine” or the “Company”), announced today that the government of Québec through Investissement Québec (IQ), an important catalyst for the Province of Quebec economic development, granted up to $1.72 million (CAD), in the form of a non-refundable contribution to fast track commercialization of the E-Motion™ 180. “I am honored and proud of what my team has been able to accomplish in such a short period of time. We have been able to demonstrate that our proprietary technology will be a disrupter within the industry. This grant will help to allow us to equip watercraft from major manufacturers to showcase E-Motion’s™ performance and range,”...

Continue reading

Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States

NATESTO® Coverage now Includes 85% of Commercial Lives TORONTO, June 29, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, effective July 1, 2021, an additional leading pharmacy benefit manager (PBM) in the United States has elected to make NATESTO® (testosterone nasal gel) a “Preferred Brand” on its National Preferred Drug List. “This new formulary placement is another key milestone in Acerus’ commercial efforts in the United States,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “We now have, without a doubt, best-in-class branded coverage, which we anticipate will lead to enhanced patient access and increased physician prescribing...

Continue reading

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable, and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer...

Continue reading

Builders FirstSource to Acquire WTS Paradigm, LLC, a Software Solutions and Services Provider for the Building Products Industry

Transaction accelerates annual billion dollar digital opportunity for Builders FirstSource and advances its strategy to invest in innovative digital solutions that help customers build more efficiently Paradigm’s technology will drive efficiencies and productivity in the building supply chain, enhancing Builders FirstSource’s portfolio of value-added products and services Enhanced digital solutions are expected to improve customer satisfaction and drive growth and operating efficiency for Builders FirstSource’s distribution business DALLAS, June 29, 2021 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (Nasdaq: BLDR) (“Builders FirstSource”), today announced that it has entered into a definitive agreement to acquire WTS Paradigm, LLC (“Paradigm”), a software solutions and services provider for the building products industry, in a...

Continue reading

Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors

Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. PHILADELPHIA, June 29, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors, effective upon the closing of the previously announced merger (the “Merger”) between Renovacor and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”). The closing of the Merger is expected to occur in the third quarter of 2021. Upon the close of the Merger, Mr. Covino will also serve as the Chair of Renovacor’s...

Continue reading

FactSet Reports Solid Results for Third Quarter 2021

Record Quarterly Revenue Hits $400 Million NORWALK, Conn., June 29, 2021 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced results for its third quarter ended May 31, 2021. Third Quarter Fiscal 2021 HighlightsRevenue increased 6.8%, or $25.5 million, to $399.6 million compared with $374.1 million for the same period in fiscal 2020. The increase is primarily due to higher sales of analytics and content and technology solutions (CTS). Organic revenues grew 5.9% to $397.4 million during the third quarter of fiscal 2021 from the prior year period.Annual Subscription Value (ASV) plus professional services was $1.6 billion at May 31, 2021, compared with $1.5 billion...

Continue reading

Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)

Company announcement – No. 43/ 2021 Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)Company to present three posters, including two on glepaglutide for the treatment of Short Bowel Syndrome (SBS) Data demonstrate potential dosing benefits of glepaglutide for patients with SBSCopenhagen, DK and Boston, MA, U.S. June 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced it will present three posters at the upcoming 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA), which is being held both virtually and in Auckland, New Zealand June 30-July 2, 2021. The Company’s...

Continue reading

Real People Investment Holdings Limited – Audited Annual Financial Statements for 2021, Amended Financial Covenants and Guidance Regarding Expected Bond Repayments

RPIH publishes its audited annual financial statements for the financial year 2021 The audited annual financial statements for 2021 is available to download at www.realpeoplegroup.co.za. Amended financial covenants Pursuant to the terms and conditions (as amended by a written procedure completed on 21 September 2020) (the “Terms and Conditions“) for the up to SEK 260,000,000 and up to NOK 135,000,000 senior unsecured callable bonds 2013/2028 with ISIN: SE0005392560 and NO0010689342 (the “Bonds“) issued by Real People Investment Holdings Limited (the “Issuer” or “RPIH“), the Issuer shall comply with the undertakings to uphold specified levels of financial ratios for relevant measurement periods from time to time, as prescribed in the senior unsecured loan agreement entered into between the...

Continue reading

System1, a Leading Omnichannel Customer Acquisition Platform, to Become a Publicly Listed Company Through a Business Combination With Trebia Acquisition Corp.

System1, a fast-growing and profitable omnichannel customer acquisition platform, will be valued at $1.4 billion in connection with the transaction.The growth capital provided by the transaction will accelerate System1’s leading position as a privacy-centric digital marketer, allow for investment in its proprietary technology platform (Responsive Acquisition Marketing Platform, or RAMP) and complete its acquisition of Protected.net.The transaction includes up to $600 million of fully committed financing, comprised of a debt commitment of up to $400 million and a $200 million equity backstop from Cannae Holdings, Inc. (NYSE: CNNE) that, together with a portion of the debt commitment, will be utilized as a backstop for potential future Trebia redemptions. This backstop combined with the potential for management to roll additional...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.